GLP-1 · Cost comparison
GLP-1 Patches vs. Prescription
How transdermal patches compare to prescription semaglutide and tirzepatide on effectiveness, real monthly cost, and how to get each.
Disclosure: We earn a commission if you sign up with some of the providers listed on this page. It doesn’t change what you pay, and it doesn’t change our assessments — our grading criteria are published below and applied identically to every provider, including ones we don’t earn from.
The short version
| Transdermal patch | Prescription GLP-1 | |
|---|---|---|
| Active ingredient | Herbal extracts, minerals | Semaglutide or tirzepatide |
| Contains an actual GLP-1? | No | Yes |
| Clinical evidence | None for meaningful weight loss | Large randomised trials |
| Typical results | Not demonstrated | −14.9% (semaglutide, 2.4 mg) to −20.9% (tirzepatide, 15 mg) |
| Monthly cost | $40–$80 | $249–$598 all-in, depending on provider and dose |
| Prescription needed | No | Yes |
| Medical oversight | None | Licensed prescriber |
| Delivery | Adhesive patch | Weekly injection or daily tablet |
The comparison isn’t close, and the reason is physical rather than commercial. Semaglutide weighs roughly 4,114 daltons; intact skin doesn’t passively absorb molecules much above 500. No patch formulation gets around that. We covered the full explanation in Do GLP-1 patches actually work?
Effectiveness
- Patches. There are no published randomized controlled trials showing meaningful weight loss from a transdermal GLP-1 or “GLP-1 support” patch. What exists is testimonial marketing and, in a few cases, oral-dose research on individual ingredients presented as though it transfers to a patch. It doesn’t — berberine’s glucose studies used roughly 500 mg taken several times daily, a quantity no adhesive patch delivers.
- Prescription GLP-1s. The evidence base is among the strongest in obesity medicine. In pivotal trials, semaglutide at the weight-management dose produced −14.9% average body weight reduction over 68 weeks (2.4 mg, STEP 1), and tirzepatide produced −20.9% over 72 weeks (15 mg, SURMOUNT-1), both alongside lifestyle intervention. Individual results vary widely, and roughly a third of participants in these trials achieved substantially more than the average while some achieved considerably less.
Two caveats that honest coverage should include. These results were achieved with continued use — weight regain after discontinuation is well documented. And the trials included structured diet and activity support, which is part of why platforms that bundle coaching may be worth more than their price difference suggests.
Each trial figure is a single dose arm, and the two come from separate trials rather than a head-to-head comparison. Tirzepatide’s lowest studied dose (5 mg) produced −15.0%, about the same as semaglutide at 2.4 mg.
What each actually costs
Patches run $40 to $80 a month, often on a subscription. For a product with no demonstrated effect, the correct way to think about that number isn’t “cheap” — it’s $480 to $960 a year for nothing. The same question applies to the oral products sold as GLP-1 supplements.
Prescription pricing is harder to pin down than it looks. Based on published provider pricing in August 2026, real all-in monthly costs run from roughly $249 to $598 depending on the platform, the medication, the dose, and whether you prepay. Headline figures are consistently lower than that, because most platforms advertise one half of the cost.
Worth knowing
The pricing trap: advertised prices frequently exclude the medication itself. One provider’s “from $149” is a medication price that requires a separate $149 monthly membership — a real minimum of $298.
Ask before you sign up
- Is the membership fee separate from the medication cost?
- Is the advertised rate a first-month promotional price?
- Is billing monthly, or in three-month blocks?
- Are labs, shipping, and dose escalations included?
- What happens to your price when your dose increases?
Ask for the total twelve-month cost at a maintenance dose. That single question cuts through most of it — and as the table below shows, only one of the three largest platforms publishes enough to answer it.
Comparing licensed providers
How we grade. Four criteria, applied to every provider. The full comparison, with per-dose pricing and twelve-month totals, is on our licensed telehealth providers page:
- LegitScript certification — the third-party healthcare merchant credential that Google and the major ad platforms require before an online clinic can advertise. Its absence isn’t proof of a problem, but it’s a meaningful flag.
- Pharmacy transparency — whether the platform publicly names which pharmacy fills your prescription. Only an estimated 15–20% of US telehealth GLP-1 providers do.
- Branded vs. compounded — FDA-approved branded medication has been through the full approval process. Compounded versions have not, and the regulatory ground under compounded GLP-1s shifted substantially in 2025 and 2026.
- True all-in cost — the twelve-month total at a maintenance dose, not the advertised headline.
| Provider | LegitScript | Medication | Names pharmacy | All-in monthly | 12 months at maintenance |
|---|---|---|---|---|---|
| Hims & Hers | Badge displayed; status not independently verified | Branded, with compounded retained on a limited scale | Partial — named in SEC filings, not on consumer pages | $298–$448 (starting dose) | Not published |
| Ro | Badge displayed; status not independently verified | Branded | No | $373–$598 | $4,476–$7,176 |
| Noom | Badge displayed; status not independently verified | Both — compounded and branded, on separate plans | No | $249 or $279 (sources conflict) | Unresolved |
Pricing observed 25 August 2026 from each provider’s own published pages. We could not independently verify LegitScript certification for any of the three: the registry lookup is CAPTCHA-gated, and all we can confirm is that each displays a badge on its own site — which is the provider’s claim, not a verification. We do not print a certification we have not checked.
What each platform is actually like
- Hims & Hers — the most institutionally accountable option on the list. Publicly traded with SEC reporting obligations, licensed providers in every state where it prescribes, and pharmacy partners named in its filings. It announced in March 2026 that it would stop advertising compounded GLP-1s and move patients to FDA-approved medication, retaining compounded semaglutide only where clinical needs cannot be met commercially. Its pricing is the least transparent of the three: the advertised figure is medication only, a $149 monthly membership is mandatory and billed separately, and no price is published for any dose above the starting dose. Weaker on customer support — limited access to actual humans, slow responses.
- Ro — branded-only, available in all fifty states, and the strongest insurance navigation of the major platforms. If there’s any chance your plan covers a GLP-1, Ro is the one that will find out. It is also the only provider of the three that publishes a full dose-tiered price table, which is why it is the only one where a twelve-month maintenance cost can actually be calculated. That transparency cuts both ways: its own table shows the advertised $199 pen price is a starting-dose promotion against a $349 regular rate.
- Noom — the best option if you want coaching bundled rather than bolted on, and the only one whose compounded plans include the medication in the price rather than billing it separately. Three reservations. It still dispenses compounded medication on those plans and declines to name its pharmacies. Its own pages quote two different recurring prices for the same program. And its “month” is a four-week block, not a calendar month — so a year contains thirteen billing periods, not twelve, which raises the annual cost above what the monthly figure implies.
How to get a prescription
The process at a licensed telehealth platform is straightforward and typically takes a few days end to end.
- Intake questionnaire. Medical history, current medications, height and weight, and your goals. Answer accurately — the contraindications matter.
- Clinical review. A licensed provider in your state reviews the intake. Some platforms use asynchronous review, others require a video visit. A few request recent lab work.
- Eligibility determination. Prescribing generally follows BMI-based criteria: roughly 30 and above, or 27 and above with a weight-related condition such as hypertension, sleep apnea, or type 2 diabetes.
- Prescription and fulfillment. Sent to a partner pharmacy, shipped cold-chain to your door, usually within a week.
- Ongoing care. Periodic check-ins, dose adjustments, side-effect management.
You can be declined. If you are, that’s the system functioning correctly rather than failing.
Who these medications aren’t for
Our scope
We’re not in a position to tell you whether a GLP-1 is appropriate for you. We don’t employ clinicians and we’ve never met you.
What follows is drawn from approved prescribing information and standard eligibility criteria, so you know what a provider will screen for. Approved labeling lists contraindications or cautions for people who:
- Have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Have had pancreatitis
- Are pregnant, nursing, or planning pregnancy
- Have a history of an eating disorder — appetite suppression can interact badly with restrictive patterns, and this warrants a conversation with a clinician who knows your history rather than an online intake form
- Have significant gastrointestinal disease, including gastroparesis
- Have type 1 diabetes
There’s also a category of people for whom these medications simply aren’t indicated: anyone at a healthy weight looking to lose a small amount. The trials studied people with obesity or with overweight plus a related condition. Outside that population the risk-benefit calculation is different, and a legitimate platform will tell you so.
Frequently asked questions
-
Is a GLP-1 patch better than nothing?
It isn’t better than nothing, because it costs money and displaces action. If prescription medication isn’t the right fit, structured nutrition and activity support has real evidence behind it and a patch doesn’t.
-
Can I get semaglutide without a prescription?
Not legally for personal use. Products sold as “research use only” peptides aren’t a workaround — the FDA has issued warning letters to sellers marketing them that way, holding that the disclaimer doesn’t apply when the surrounding marketing implies human use. These products aren’t subject to pharmaceutical manufacturing standards, and FDA testing of grey-market samples has identified impurities including heavy metals and mislabeled contents.
-
What’s the cheapest legitimate way to get a GLP-1?
Insurance coverage, if you can get it — which is why Ro’s insurance navigation matters. Failing that, annual prepayment: Ro’s twelve-month membership rate is roughly half its month-to-month rate. Be sure “cheapest” reflects the twelve-month total rather than a promotional first month.
-
Are compounded GLP-1s legal in 2026?
The picture narrowed considerably. Once the FDA declared the semaglutide and tirzepatide shortages resolved, the compounding exemptions that permitted widespread production lapsed, and enforcement has been active. Some 503A pharmacy compounding continues under specific conditions. If a platform offers compounded medication, ask directly about its current compliance posture.
-
Do I have to inject?
Not necessarily — oral formulations exist, though effect sizes have generally been smaller. Most people find the weekly injection far less difficult than anticipated; the needle is very short and fine.
Sources and method
- Provider pricing. Read directly from each provider’s own published pricing pages on 25 August 2026: Hims & Hers, Ro, Noom. Where a figure is computed, both inputs come from the provider’s own pages.
- Hims & Hers medication policy. Strategic shift announcement, 9 March 2026.
- Trial results. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJM 2021. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022.
- What we could not verify. LegitScript certification status for all three providers; Hims & Hers medication pricing above the starting dose; Ro’s prepaid medication rates; and which of Noom’s two conflicting recurring prices is current. Each is marked as unverified above rather than estimated.
Pricing verified 25 August 2026. We recheck provider pricing quarterly.